{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"7"}],"units":"Participants"}],"description":"From positive ADA samples titer values and neutralizing antibody scores (positive or negative) were determined and reported. A participant was considered positive if negative at baseline (screening) and had at least one positive post-baseline result, or positive at baseline and had at least one positive post-baseline result with a titer higher than baseline. Number of participants with ADA positive to GEN1029 are reported.","groups":[{"description":"Participants received 0.1 mg/kg of GEN1029 every 2 weeks (Q2W) until the end of treatment.","id":"OG000","title":"Biweekly Regimen (GEN1029 0.1 mg/kg)"},{"description":"Participants received 0.2 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG001","title":"Biweekly Regimen (GEN1029 0.2 mg/kg)"},{"description":"Participants received 0.3 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG002","title":"Biweekly Regimen (GEN1029 0.3 mg/kg)"},{"description":"Participants received 1.0 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG003","title":"Biweekly Regimen (GEN1029 1.0 mg/kg)"},{"description":"Participants received 2.0 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG004","title":"Biweekly Regimen (GEN1029 2.0 mg/kg)"},{"description":"Participants received 3.0 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG005","title":"Biweekly Regimen (GEN1029 3.0 mg/kg)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Immunogenicity Set consists of all participants who received at least one dose of GEN1029 and analyzed according to the actual treatment received and had at least one immunogenicity measurement taken.","reportingStatus":"POSTED","timeFrame":"From Screening (Day -21 to -1) through Day 478 (corresponding to maximum observed duration)","title":"Number of Participants With Antidrug Antibodies (ADAs) Positive to GEN1029","type":"SECONDARY","unitOfMeasure":"Participants"}